Development project to achieve CE marking on Ingenion's flagship innovative catheter product, which uses a magnetic valve that enables a patient to easily use the same catheter for up to 28 days
Development project to achieve CE marking on Ingenion's flagship innovative catheter product, which uses a magnetic valve that enables a patient to easily use the same catheter for up to 28 days
批准号:
87819
负责人:
金额:
$12.67万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --
中文摘要
对于全世界数百万患有膀胱控制障碍的患者来说,需要一种使用时间更长、更安全的导尿管。带着导尿管生活是不愉快的,往往令人尴尬,并与许多并发症有关,其中最严重的是导尿管相关性尿路感染(CAUTI)的风险。尿路感染是最常见的医院获得性感染,75%的尿路感染与导尿管治疗有关。(美国疾病控制与预防中心网站关于CAUTIs,最近更新于2015年10月)CAUTIs占所有医院获得性感染总死亡率的13%,并导致抗生素耐药性(Becker's Hospital Review, 2015年5月)。Ingenion专注于创新医疗设备的开发,由Edward Cappabianca, Zia Mursaleen和Alistair Taylor领导。该公司已经开发出一种解决方案来解决现有导管的局限性,即带有电磁阀的导管,可以安全使用长达28天。Ingenion正在寻求资金为其创新获得CE认证,以吸引更多投资并将产品销售到医疗市场,最终使患者的生活更轻松,更安全,更有尊严。该项目预计5年后的项目收入为2400万英镑。
英文摘要
There is a need for a longer-use, safer catheter for the millions of patients suffering from bladder control challenges across the world. Living with a catheter is unpleasant, often embarrassing and is associated with a number of complications, the most severe of which is the risk of Catheter-associated urinary tract infections (CAUTI). CAUTIs are the most common form of hospital-acquired infection with 75% of UTIs associated with catheter treatment. (US CDC website re CAUTIs, last updated Oct 2015) CAUTIs account for 13% of the combined mortality for all hospital-acquired infections and contributes to antibiotic resistance (Becker's Hospital Review, May 2015).Ingenion specialises in innovative medical device development and is led by Edward Cappabianca, Zia Mursaleen and Alistair Taylor. The Company has developed a solution to address the limitations of existing catheters responsible for these shortcomings -- a catheter with a magnetic valve which can be used safely for up to 28 days. Ingenion is seeking funding to CE mark its innovation in order to attract further investment and sell the product to the medical market and ultimately make patients' lives easier, safer and more dignified. This project has a projected year-five post-project revenue of £24M.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
CD8+T细胞亚群在抗MDA5抗体阳性皮肌炎中的致病机制研究
-
批准号:82371805
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:扶琼
-
依托单位:
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
-
批准号:82371144
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:汪雪玲
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
巨噬细胞通过Piezo1感知组织硬度限制肝脏纤维化的作用机制研究
-
批准号:82371760
-
项目类别:面上项目
-
资助金额:52.00万元
-
批准年份:2023
-
负责人:王静
-
依托单位:
亚洲人群的新基因和剪接外显子的发现- 通过分析和验证HapMap其他人群的转录组测序(RNA-seq)数据
-
批准号:31171213
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:邓亮生
-
依托单位: